当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.

Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.

Abstract：

BACKGROUND:The purpose of this study was to compare perioperative and oncologic outcomes between laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) for bladder cancer (BCa). MATERIALS AND METHODS:Patients who underwent LRC or RARC with curative intent for BCa between January 2011 and December 2016 were included. Perioperative, pathologic oncologic data were extracted from our database. Disease-free survival, overall survival, and cancer-specific survival were analyzed using Kaplan-Meier survival curves with log-rank tests. RESULTS:A total of 126 patients underwent LRC and 189 patients underwent RARC during the study period. All the baseline variables were similar between the two groups. Patients undergoing RARC had a significant higher median estimated blood loss (300 mL vs. 200 mL; P = .005), lower rate of 90-day postoperative complications (36.5% vs. 50.0%; P = .017), and higher median direct cost ($15,306 vs. $11,131; P < .001) than LRC. Other perioperative outcomes were similar. No differences were found in pathologic T stage, positive lymph nodes, or positive surgical margin between patients who underwent LRC and RARC. The 5-year disease-free survival, overall survival, and cancer-specific survival rates were 51.9%, 61.0%, and 69.5%, respectively, for all included patients. There were no significant differences in oncologic outcomes between the 2 groups. CONCLUSION:Patients with BCa can be safely managed with LRC and RARC by experienced surgeons. RARC was associated with a reduced rate of postoperative complication but also with higher median estimated blood loss, and higher median direct cost. These findings could be used to guide patient counseling, and treatment selection.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Su S,Gu L,Ma X,Li H,Wang B,Shi T,Zhang X

doi

10.1016/j.clgc.2019.06.007

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

e1048-e1053

issue

5

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(18)30605-0

journal_volume

17

pub_type

杂志文章

相关文献

Clinical Genitourinary Cancer文献大全
  • Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.

    abstract：BACKGROUND:Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial c...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2008.n.005

    authors： Lassiter LK,Tummala MK,Hussain MH,Stadler WM,Petrylak DP,Carducci MA

    更新日期：2008-03-01 00:00:00

  • Comparison of Patient-Reported Quality-of-Life and Complications in Men With Prostate Cancer, Between Two Modes of Administration.

    abstract：INTRODUCTION:Our purpose was to: (1) assess the level of consistency between the quality-of-life (QOL) scores of men with prostate cancer for urinary/bowel/sexual bother, collected via telephone versus self-administered survey; (2) determine factors associated with variation in level of agreement; and (3) assess the ef...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.016

    authors： Sampurno F,Ruseckaite R,Millar JL,Evans SM

    更新日期：2016-08-01 00:00:00

  • Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

    abstract：BACKGROUND:Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2016.03.006

    authors： O'Donnell PH,Alanee S,Stratton KL,Garcia-Grossman IR,Cao H,Ostrovnaya I,Plimack ER,Manschreck C,Ganshert C,Smith ND,Steinberg GD,Vijai J,Offit K,Stadler WM,Bajorin DF

    更新日期：2016-12-01 00:00:00

  • Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis.

    abstract：BACKGROUND:Neoadjuvant radiotherapy (NART) for muscle-invasive bladder cancer (MIBC) is currently underused. However, the outcomes for MIBC have remained suboptimal. We investigated the relationship of NART to cause-specific mortality (CSM) and overall mortality (OM) among patients with a diagnosis of MIBC. MATERIALS ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.02.014

    authors： Diaz DA,Pollack A,Reis IM,Mahmoud O,Gonzalgo ML,Ishkanian A,Fernandez G,Manoharan M,Abramowitz MC

    更新日期：2015-08-01 00:00:00

  • Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.

    abstract：BACKGROUND:The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.04.016

    authors： Lorente D,Omlin A,Zafeiriou Z,Nava-Rodrigues D,Pérez-López R,Pezaro C,Mehra N,Sheridan E,Figueiredo I,Riisnaes R,Miranda S,Crespo M,Flohr P,Mateo J,Altavilla A,Ferraldeschi R,Bianchini D,Attard G,Tunariu N,de Bono J

    更新日期：2016-12-01 00:00:00

  • Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.

    abstract：BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical challenge. Single immediate postoperative instillation of chemotherapy (IPIOC) is controversial for NMIBC patients with intermediate recurrence risk....

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.028

    authors： Murakami K,Hamada A,Teramoto Y,Matsumoto K,Kita Y,Saito R,Yamasaki T,Matsui Y,Inoue T,Ogawa O,Kobayashi T

    更新日期：2019-10-01 00:00:00

  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

    abstract：:Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.036

    authors： Sonpavde G,Aparicio A,Guttierez I,Boehm KA,Hutson TE,Berry WR,Asmar L,von Hoff DD

    更新日期：2007-12-01 00:00:00

  • Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer.

    abstract：INTRODUCTION:Late locoregional complications in prostate cancer (PCa) affect quality of life and require medical interventions. Our objective was to compare late locoregional complications in men dying of castration-resistant PCa (CRPC) who previously received external-beam radiotherapy (EBRT) to radical prostatectomy ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.08.011

    authors： Hu J,Aprikian AG,Cury FL,Vanhuyse M,Zakaria AS,Richard PO,Perreault S,Dragomir A

    更新日期：2017-09-05 00:00:00

  • Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy.

    abstract：INTRODUCTION:We evaluated the influence of perinephric fat invasion (PFI) compared with sinus fat invasion (SFI) on disease-free survival (DFS) and cancer-specific survival (CSS) after partial nephrectomy (PN) for stage pT3a renal cell carcinoma (RCC). MATERIALS AND METHODS:Data were recorded from the consecutive reco...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.07.019

    authors： Mouracade P,Dagenais J,Chavali JS,Kara O,Nelson RJ,Maurice MJ,Reese J,Rini BI,Kaouk JH

    更新日期：2018-10-01 00:00:00

  • Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

    abstract：BACKGROUND:Patients with biochemically recurrent prostate cancer and short prostate-specific antigen doubling time (PSADT) are at risk for metastasis yet may wish to avoid androgen deprivation therapy. Itraconazole may have antitumor activity without affecting circulating androgen levels. We therefore evaluated itracon...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.09.013

    authors： Lee M,Hong H,Kim W,Zhang L,Friedlander TW,Fong L,Lin AM,Small EJ,Wei XX,Rodvelt TJ,Miralda B,Stocksdale B,Ryan CJ,Aggarwal R

    更新日期：2019-02-01 00:00:00

  • Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.

    abstract：BACKGROUND:Radical prostatectomy (RP) can cure men with unfavorable intermediate- or high-risk prostate cancer (PC). However, some will experience short prostate-specific antigen (PSA) doubling time (PSADT) failure that requires additional treatment with increased toxicity. The present study investigated whether the gr...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.02.012

    authors： Cheney MD,Zhang D,Chen MH,Loffredo MJ,Richie JP,D'Amico AV

    更新日期：2015-08-01 00:00:00

  • Partial nephrectomy for the treatment of translocation renal cell carcinoma.

    abstract：BACKGROUND:The aim of this study was to evaluate the outcome of patients with translocation renal cell carcinoma (RCC) treated with partial nephrectomy. PATIENTS AND METHODS:Our institutional review board-approved renal mass registry was queried for patients who underwent partial nephrectomy for a pathologically confi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.12.008

    authors： Gorin MA,Ball MW,Pierorazio PM,Argani P,Allaf ME

    更新日期：2015-06-01 00:00:00

  • Correlation Between the Timing of Diagnostic Ureteroscopy and Intravesical Recurrence in Upper Tract Urothelial Cancer.

    abstract：UNLABELLED:To identify the effects of diagnostic ureteroscopy on intravesical recurrence, 104 patients who had undergone radical nephroureterectomy were analyzed. The number of patients with intravesical recurrence was 34 (32.6%) at a mean of 37 months. Multivariate Cox model analysis revealed that delayed nephroureter...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.07.008

    authors： Lee JK,Kim KB,Park YH,Oh JJ,Lee S,Jeong CW,Jeong SJ,Hong SK,Byun SS,Lee SE

    更新日期：2016-02-01 00:00:00

  • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

    abstract：PURPOSE:Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma. However, only a subset of patients appears to derive significant tumor responses. In an effort to identify potential predictors of response to...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.020

    authors： Cho D,Signoretti S,Dabora S,Regan M,Seeley A,Mariotti M,Youmans A,Polivy A,Mandato L,McDermott D,Stanbridge E,Atkins M

    更新日期：2007-09-01 00:00:00

  • Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesion ≥ 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience.

    abstract：INTRODUCTION:Magnetic resonance imaging (MRI)-ultrasound fusion targeted prostate biopsy (FB) has been advocated by many experts as a replacement for the standard template biopsy. Herein, we compared pathology results and cancer detection rates of FB with our standard 14-core systematic prostate biopsy (SB) that includ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.09.006

    authors： Sterling J,Smith K,Farber N,Nagaya N,Jang TL,Singer EA,Sadimin E,Kim IY

    更新日期：2020-10-13 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract：BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.03.006

    authors： Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期：2019-08-01 00:00:00

  • The current and emerging role of immunotherapy in prostate cancer.

    abstract：:Recent phase III trial results have demonstrated the effectiveness of sipuleucel-T, a therapeutic cancer vaccine, in the treatment of metastatic prostate cancer. Yet, despite the survival benefit of sipuleucel-T, questions remain about how immunologic agents can be used in the treatment of metastatic prostate cancer. ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CGC.2010.n.002

    authors： Madan RA,Gulley JL

    更新日期：2010-12-01 00:00:00

  • Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.

    abstract：PURPOSE:Anemia is a common morbidity of advanced prostate cancer, and prostate cancer treatment and has been associated with a worse overall survival and reduced quality of life in patients with prostate cancer. We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.012

    authors： Beer TM,Bergenstock M,Birt K,Higano CS

    更新日期：2007-06-01 00:00:00

  • Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

    abstract：BACKGROUND:Combination platinum chemotherapy is standard first-line therapy for metastatic urothelial carcinoma (mUC). Defining the platinum response biomarkers for patients with mUC could establish personalize medicine and provide insights into mUC biology. Although DNA repair mechanisms have been hypothesized to medi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.029

    authors： Mullane SA,Werner L,Guancial EA,Lis RT,Stack EC,Loda M,Kantoff PW,Choueiri TK,Rosenberg J,Bellmunt J

    更新日期：2016-08-01 00:00:00

  • Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.

    abstract：BACKGROUND:Abiraterone acetate has been approved for metastatic castration-resistant prostate cancer (mCRPC). Coadministration with prednisone has been recommended to prevent the toxicity from secondary mineralocorticoid excess, such as hypertension, hypokalemia, and edema. However, the use of prednisone is often not d...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.12.008

    authors： Gill D,Gaston D,Bailey E,Hahn A,Gupta S,Batten J,Alex A,Boucher K,Stenehjem D,Agarwal N

    更新日期：2017-08-01 00:00:00

  • Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients.

    abstract：BACKGROUND:Enzalutamide is active in advanced castration-resistant prostate cancer (CRPC) patients, in whom it has shown to be able to increase survival. We report the enzalutamide effect on primary prostate tumors, assessed by changes of metabolic tumor activity detected by (18)F-fluorocholine-positron emission tomogr...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.03.004

    authors： Caffo O,Maines F,Donner D,Veccia A,Chierichetti F,Galligioni E

    更新日期：2014-10-01 00:00:00

  • Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes.

    abstract：BACKGROUND:The purpose of this study was to evaluate morbidity, functional, and oncological outcomes after NSS in renal tumors > 7 cm. MATERIALS AND METHODS:We retrospectively analyzed data from 168 patients with tumors > 7 cm who were treated using NSS between 1998 and 2012. RESULTS:Imperative and elective indicatio...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.09.004

    authors： Bigot P,Hétet JF,Bernhard JC,Fardoun T,Audenet F,Xylinas E,Ploussard G,Pignot G,Bessede T,Ouzaid I,Robine E,Brureau L,Merigot de Treigny O,Maurin C,Long JA,Rouffilange J,Hoarau N,Lebdai S,Rouprêt M,Bastien L,Neuzi

    更新日期：2014-02-01 00:00:00

  • Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.

    abstract：BACKGROUND:The prognostic value of molecular markers in renal cell carcinoma has been investigated in several studies. Although their value is still not confirmed, various proteins are important. We describe the effect on long-term survival of the status of the von Hippel-Lindau (VHL) hypoxia-inducible factor 1-α (HIF1...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.05.016

    authors： Salinas-Sánchez AS,Serrano-Oviedo L,Nam-Cha SY,Roche-Losada O,Sánchez-Prieto R,Giménez-Bachs JM

    更新日期：2017-12-01 00:00:00

  • Secondary hormonal therapy in men with castration-resistant prostate cancer.

    abstract：BACKGROUND:Androgen receptor (AR) signaling remains important in castration-resistant prostate cancer (CRPC) and sequential responses to hormonal therapies are observed. Little is known about the factors associated with responsiveness to secondary hormone therapy (HT). METHODS:We retrospectively identified patients wi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2011.06.006

    authors： Nakabayashi M,Werner L,Oh WK,Regan MM,Kantoff PW,Taplin ME

    更新日期：2011-12-01 00:00:00

  • Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.

    abstract：BACKGROUND:Carcinoma of the collecting ducts (CDC) of Bellini of the kidney is very rare but is among the most aggressive urologic entities. PATIENTS AND METHODS:Radical nephrectomy revealed CDC in stage pT3a pN2 M0 G3 in 2 male patients. Four courses of adjuvant chemotherapy with cisplatin and gemcitabine were given....

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.010

    authors： Staehler M,Schöppler G,Haseke N,Stadler T,Karl A,Siebels M,Ihrler S,Stief CG

    更新日期：2009-01-01 00:00:00

  • Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.

    abstract：BACKGROUND:Cabozantinib showed efficacy and manageable toxicity in patients with metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to collect evidence on the potential efficacy of cabozantinib in mRCC patients with brain metastases (BM) in a real-world experience. MATERIALS AND ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.002

    authors： Peverelli G,Raimondi A,Ratta R,Verzoni E,Bregni M,Cortesi E,Cartenì G,Fornarini G,Facchini G,Buti S,Galli L,Tucci M,Prisciandaro M,Procopio G

    更新日期：2019-08-01 00:00:00

  • National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009.

    abstract：BACKGROUND:Three randomized trials demonstrated that postprostatectomy adjuvant radiotherapy improves biochemical disease-free survival for patients with adverse pathologic features, and 1 trial found adjuvant radiotherapy improves overall survival. We sought to determine whether postprostatectomy radiotherapy (PPRT) u...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.12.005

    authors： Mahal BA,Hoffman KE,Efstathiou JA,Nguyen PL

    更新日期：2015-06-01 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract：:The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.006

    authors： Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期：2007-03-01 00:00:00

  • Effect of perioperative blood transfusion on mortality for major urologic malignancies.

    abstract：INTRODUCTION:Patients who undergo surgical treatment for malignancy often receive perioperative blood transfusion (PBT). We examined the association between PBT and mortality in patients who received surgical treatment of prostate, bladder, and kidney cancer. MATERIALS AND METHODS:Using the Surveillance, Epidemiology,...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.12.006

    authors： Soubra A,Zabell JR,Adejoro O,Konety BR

    更新日期：2015-06-01 00:00:00

  • Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma.

    abstract：BACKGROUND:Upper urinary tract urothelial carcinoma (UUTUC) is one of the uncommon malignancies lacking of prognostic indicators. Lactate dehydrogenase (LDH) has been demonstrated to correlate with clinical outcomes in human cancers. In this study, we aimed to evaluate the prognostic implication of the preoperative LDH...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.01.003

    authors： Zhang XK,Zhang ZL,Lu X,Yang P,Cai MY,Hu WM,Yun JP,Zhou FJ,Qian CN,Cao Y

    更新日期：2016-08-01 00:00:00